Interaction between rifaximin and dietary fibre in patients with diverticular disease

Aliment Pharmacol Ther. 2007 Apr 1;25(7):771-9. doi: 10.1111/j.1365-2036.2007.03266.x.

Abstract

Background: Cyclic administration of rifaximin in association with dietary fibre achieves symptomatic relief in uncomplicated diverticular disease (DD) by means of a still undefined mechanism.

Aim: To investigate the effects of a combination of rifaximin and fibre on both hydrogen production by intestinal microflora and oro-anal transit time.

Methods: In a controlled, double-blind crossover trial, 64 patients with uncomplicated DD were given bran (20 g/day) and randomly treated with rifaximin (1200 mg/day) or a placebo for 14 days. Evaluation was based on clinical status, breath test, oro-anal transit time and faecal weight.

Results: The global symptomatic score was significantly reduced after rifaximin (7.1 +/- 4.1 to 4.1 +/- 3.3; P < 0.005) but not after placebo (6.8 +/- 3.8 to 6.1 +/- 3.5). Hydrogen production significantly increased after placebo from 198 +/- 134 to 267 +/- 161 ppm/min, while Rifaximin reduced it from 222 +/- 187 to 166 +/- 131 ppm/min (P = 0.05). The total oro-anal transit time decreased from 56.1 +/- 28.2 to 51.3 +/- 28.0 h in placebo and from 54.4 +/- 31.9 to 45.1 +/- 32.4 h (P < 0.05) in rifaximin-treated patients.

Conclusions: The administration of rifamixin improves the benefits of dietary fibre in uncomplicated DD by preventing its bacterial degradation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Breath Tests
  • Cross-Over Studies
  • Dietary Fiber / administration & dosage*
  • Diverticulum / drug therapy*
  • Diverticulum / etiology
  • Double-Blind Method
  • Drug Interactions
  • Female
  • Follow-Up Studies
  • Gastrointestinal Transit / drug effects
  • Humans
  • Hydrogen / metabolism
  • Male
  • Middle Aged
  • Patient Compliance
  • Rifamycins / pharmacology
  • Rifamycins / therapeutic use*
  • Rifaximin

Substances

  • Anti-Infective Agents
  • Dietary Fiber
  • Rifamycins
  • Hydrogen
  • Rifaximin